Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 7, 2022
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
Ed Arce Maintained (AUPH) at Strong Buy with Decreased Target to $14 on, Nov 7th, 2022
Ed Arce of HC Wainwright & Co., Maintained "Aurinia Pharmaceuticals Inc." (AUPH) at Strong Buy with Decreased Target from $26 to $14 on, Nov 7th, 2022.
Ed has made no other calls on AUPH in the last 4 months.
There are 3 other peers that have a rating on AUPH. Out of the 3 peers that are also analyzing AUPH, 1 agrees with Ed's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Justin Kim of "Oppenheimer" Downgraded from Buy to Hold on, Friday, November 4th, 2022
These are the ratings of the 2 analyists that currently disagree with Ed
- Douglas Miehm of "RBC Capital" Maintained at Buy with Decreased Target to $10 on, Friday, November 4th, 2022
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $12 on, Friday, November 4th, 2022
